-
Mashup Score: 88Tumor-selective treatment of metastatic pancreatic cancer with an engineered, probiotic living drug - 13 day(s) ago
Pancreatic ductal adenocarcinoma (PDAC) poses significant challenges for effective treatment, with systemic chemotherapy often proving inadequate due to poor drug delivery and the tumor’s immunosuppressive microenvironment. Engineered bacteria present a novel approach to target PDAC, leveraging their ability to colonize tumors and deliver therapeutic payloads. Here, we engineered probiotic Escherichia coli Nissle 1917 (EcN) to produce the pore-forming Theta toxin (Nis-Theta) and evaluated its efficacy in a preclinical model of PDAC. Probiotic administration resulted in selective colonization of tumor tissue, leading to improved overall survival compared to standard chemotherapy. Moreover, this strain exhibited cytotoxic effects on both primary and distant tumor lesions while sparing normal tissues. Importantly, treatment also modulated the tumor microenvironment by increasing anti-tumor immune cell populations and reducing immunosuppressive markers. These findings demonstrate the poten
Source: www.biorxiv.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8Phases of Metabolic and Soft Tissue Changes in Months Preceding a Diagnosis of Pancreatic Ductal Adenocarcinoma - 13 day(s) ago
Identifying metabolic abnormalities that occur before pancreatic ductal adenocarcinoma (PDAC) diagnosis could increase chances for early detection. We collected data on changes in metabolic parameters (glucose, serum lipids, triglycerides; total, low-density, and high-density cholesterol; and total body weight) and soft tissues (abdominal subcutaneous fat [SAT], adipose tissue, visceral adipose tissue [VAT], and muscle) from patients 5 years before the received a diagnosis of PDAC.
Source: www.gastrojournal.orgCategories: General Medicine News, Hem/OncsTweet-
Prior study summary graphic below: Phases of Metabolic and Soft Tissue Changes in Months Preceding a Diagnosis of #PancreaticCancer https://t.co/EU1QycMkKl Body composition changes especially VAT/SAT changes and biochemical metabolic perturbations (serum lipids and glucose) can… https://t.co/25SA31UDGH https://t.co/ube18aKjx9
-
-
Mashup Score: 51Multiplexed Imaging Mass Cytometry Analysis Characterizes the Vascular Niche in Pancreatic Cancer - 16 day(s) ago
Abstract. Oncogenesis and progression of pancreatic ductal adenocarcinoma (PDAC) is driven by complex interactions between the neoplastic component and the tumor microenvironment (TME), which includes immune, stromal, and parenchymal cells. In particular, most PDACs are characterized by a hypovascular and hypoxic environment that alters tumor cell behavior and limits the efficacy of chemotherapy and immunotherapy. Characterization of the spatial features of the vascular niche could advance our understanding of inter- and intra-tumoral heterogeneity in PDAC. Here, we investigated the vascular microenvironment of PDAC by applying imaging mass cytometry using a 26-antibody panel on 35 regions of interest (ROIs) across 9 patients, capturing over 140,000 single cells. The approach distinguished major cell types, including multiple populations of lymphoid and myeloid cells, endocrine cells, ductal cells, stromal cells, and endothelial cells. Evaluation of cellular neighborhoods identified 10
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 36Germline Testing identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors - 23 day(s) ago
Abstract. 10% of pancreatic neuroendocrine tumors (pNETs) are related to inherited syndromes (MEN1, MEN4, VHL, NF1, TSC). Growing evidence suggests that clinically sporadic pNETs can also harbor germline pathogenic variants. In this study, we report the prevalence of pathological/likely pathological germline variants (P/LP) in a high-risk cohort and an unselected cohort. We collected clinical data of patients with pNETs seen at MD Anderson Cancer Center (MDACC) and Johns Hopkins Hospital (JHH). High-risk cohort included (n=132) patients seen at MDACC who underwent germline testing for high-risk criteria (early onset, personal or family history of cancer and syndromic features) between 2013-2019. Unselected cohort (n=106) patients seen at JHH who underwent germline testing following their diagnosis of pNETs between 2020 to 2022. In the high-risk cohort (n=132), 33% (n=44) had P/LP variants. The majority of the patients had P/LP variants in MEN1 56% (n=25), followed by DNA repair pathway
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet-
In @CAPR_AACR from @hopkinskimmel & @MDAndersonNews #PancreaticCancer teams: Germline Testing identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors https://t.co/PPLsGC8wT4 In an unselected population, 1 in 5 harbor germline alterations… https://t.co/nb8IGxwIbU
-
-
Mashup Score: 30
Abstract. Pancreatic cancer prevalence increases with age, and disease prognosis is poorer in older individuals. The increased prevalence is driven, undoubtedly, by the multistep accumulation of oncogenic mutations in cancer cells with age. However, fibroblasts are major constituents and key players in pancreatic cancer, and they too undergo age-related changes that may contribute to disease severity. In this issue of Cancer Research, Zabransky and colleagues set out to dissect the effect of age-related changes in pancreatic fibroblasts on pancreatic ductal adenocarcinoma growth and metastasis. They discovered that aged fibroblasts secrete GDF-15, which in turn activates AKT signaling and accelerates tumor progression. These findings provide a mechanistic role for aged fibroblasts in pancreatic cancer, underpinning the importance of normal physiologic processes in tumor progression.See related article by Zabransky et al., p. 1221
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Effect of surgery versus chemotherapy in pancreatic cancer patients: a target trial emulation - 24 day(s) ago
AbstractBackground. To estimate the causal effect of surgery vs chemotherapy on survival in patients with T1-3NxM0 pancreatic cancer in a rigorous framewor
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 93Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma - 26 day(s) ago
Transcriptomic-based tumor microenvironment classification identifies 4 prognostically distinct pancreatic ductal adenocarcinoma subtypes that can serve as a framework for patient selection to precision medicine trials.
Source: www.gastrojournal.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4
The International Journal of Cancer is a cancer journal from the Union for International Cancer Control covering experimental and clinical cancer research.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Liquid Biopsy Has Near-Perfect Accuracy for Early Pancreatic Cancer - 1 month(s) ago
Researchers develop signature for pancreatic cancer based on microRNAs and cell-free DNA markers in the blood of patients with the disease.
Source: www.mdedge.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1Patrick Swayze’s Widow Reflects His Cancer, Demi Moore Speaks About Breast Cancer and More - 1 month(s) ago
From Patrick Swayze’s widow recalling his pancreatic cancer diagnosis to Demi Moore speaking about her aunt’s courage during cancer, here’s what’s going on in the oncology space this week.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
Cool “bugs as drugs” preprint from @KenOliveLab to start off your Monday. Really great stuff Ken (who is on a roll!) Tumor-selective treatment of metastatic #PancreaticCancer with an engineered, probiotic living drug https://t.co/tnt4uh36wg Photomicrograph showing acylhomoserine… https://t.co/IujYBQicjn https://t.co/djCWyW7P2n